Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The headline On Thursday 21 May 2026, Eli Lilly announced that participants in TRIUMPH-1, the first Phase 3 trial of retatrutide in obesity, lost an average of 28.3% of their body weight at 80 weeks on the 12 mg dose, with 45.3% losing at least 30% of their starting weight [1]
Before switching or starting either medication, talk to your doctor
Laboratory handling requires adherence to sterile preparation and once weekly injection standards to maintain sample integrity
Conclusion: The outlook for state Medicaid coverage of GLP-1 AOMs While 13 state Medicaid programs covered at least one GLP-1 approved for weight management as of August 2024, states subsequently reversed course: California, New Hampshire, Pennsylvania, and South Carolina recently withdrew coverage
In one study, over 90% of participants in a group weight loss program made effective weight loss gains over the course of their time together
Use separate injection sites, at least 2 inches apart, typically alternating sides of the abdomen or using one abdominal site and one thigh site
